Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients

Hyeyoung Lee¹,², Eunhee Han¹, Ae-Ran Choi¹, Tae Hyun Ban³, Byung Ha Chung³, Chul Woo Yang³, Yeong Jin Choi⁴, Eun-Jee Oh¹*¹

¹ Department of Laboratory Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, ² Department of Laboratory Medicine, International St. Mary’s Hospital, College of Medicine, Catholic Kwandong University, Incheon, Korea, ³ Division of Nephrology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, ⁴ Department of Hospital Pathology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

* ejoh@catholic.ac.kr

Abstract

Introduction
Complement binding activity of donor-specific HLA antibodies (DSA) has been suggested as a new tool to stratify immunologic risk in kidney transplantation (KT). The objective of this study was to evaluate the clinical implication of C1q/C3d binding activity of de novo DSA (dnDSA) in KT recipients.

Material and methods
A total of 161 pretransplant DSA-negative recipients were monitored for dnDSA at the time of biopsy. C1q/C3d binding activities of dnDSA were assessed using C1qScreen assay (One lambda, USA) and Lifecodes C3d detection assay (Immucor, USA), respectively. Clinical outcomes including biopsy-proven antibody mediated rejection (AMR), C4d detection and post-biopsy graft survival were investigated.

Results
De-novo DSAs were detected in fifty-four (33.5%) patients (HLA class I only, n = 19; class II only, n = 29; both class I and II, n = 6). Of them, complement binding activities were detected in 26 (48.1%) patients, including 17 C1q+ and 24 C3d+ patients. Both C1q and C3d positivity were associated with increased mean fluorescence intensity values of dnDSA. Complement binding activity of dnDSA enhanced the incidence of AMR (25.0% in C1q-C3d-, 36.4% in C1q+/C3d- or C1q-/C3d+, and 60.0% in C1q+/C3d+ patients) (P <0.001). The incidence of AMR was not different between patients with C1q+ and those with C3d+ dnDSA (64.7%, 11/17 versus 45.8%, 11/24, P = 0.238). In comparison between C1q and C3d assay according to HLA specificity, C1q+ HLA class I±II dnDSA was the best predictor for AMR (odds ratio: 27.2). C1q+/C3d+ dnDSA was associated with more C4d deposition in allograft tissue and inferior...
post-biopsy graft survival. Clinical outcomes were not significantly different between C1q+ and C3d+ dnDSA-positive patients.

**Conclusion**

Detection of complement binding activity using both C1q and C3d assays can be a further prognostic marker for predicting AMR and allograft outcome in dnDSA+ kidney transplant patients.

**Introduction**

Even with the development of strong immunosuppressive regimens, antibody mediated rejection (AMR) is a leading cause of long term kidney allograft loss [1]. Detection of antibodies against donor specific HLA antigens (DSA) initiates sequence of immune injuries in AMR [2]. Single antigen bead (SAB) assay based on Luminex platform has become a standard tool for detecting DSA in transplant patients [3, 4]. *De novo* DSA (dnDSA) can detect about 7–29% of kidney transplant recipients when it is tested with SAB [5, 6]. It has been reported that dnDSAs are associated with acute and chronic antibody mediated rejections [7–10], chronic graft dysfunction [9], and low allograft survival [11, 12].

Although DSAs can induce a wide range of graft injuries from no damage to severe rejection, as not all DSAs are responsible for causing AMR or for the inferior outcome of transplant [2, 13, 14]. Since improved analysis is needed to better distinguish clinically relevant DSA, SAB assays for detecting complement-binding activity of HLA antibodies (C1q, C3d) have been introduced [15, 16] with the hypothesis that complement binding antibodies are more harmful to the graft compared with their non-activating counterparts [2]. C1q is the first component in the classic complement pathway and C3d is a cleavage product of C3 in the downstream of complement cascade. Several studies have shown the association of C1q or C3d binding DSAs with AMR or poor graft survival [15–22]. Although several studies have compared two complement-binding assay [15, 22–24], their results are controversial as the superiority or difference of diagnostic utility remains unclear. The objective of this study was to test both C1q and C3d binding activities of dnDSA at the time of biopsy and investigate histopathological and clinical impact of them in kidney transplant patients.

**Materials and methods**

**Study population**

Among 2,333 patients who received renal transplants between March 1988 and February 2016, we included 161 adult recipients who were pretransplant DSA negative and underwent indication biopsy and DSA testing between February 2010 and May 2016 at Seoul St. Mary’s hospital (Fig 1). The baseline characteristics are summarized in Table 1. The immunosuppressive regimen at our hospital has been previously described [25, 26]. Pretransplant desensitization was performed in four patients who received ABO-incompatible transplants and five patients with pre-transplant high PRA (≥ 50%) despite no DSA [27, 28]. Tacrolimus or cyclosporine was administered with mycophenolate mofetil and prednisolone for initial immunosuppressant. Basiliximab was administered as an additional induction therapy. Indication biopsy was performed for patients with an increase in serum creatinine level (20% above baseline value) or new-onset of proteinuria. The median time to biopsy was 8.0 months (interquartile range: 1.5–64.3) after KT. And the median follow-up time after biopsy was 47.7 (interquartile range:...
24.7–63.9) months. This study was approved by the Institutional Review Board of Seoul St. Mary’s Hospital (KC13TNMI0701). Of 161 recipients, informed written consents were obtained from 128 patients. For 33 patients who received KT before January 2013, informed consent was waived by the board (KC10SISI0057) because the current retrospective study was performed using medical records and leftover serum specimen.

Detection of donor specific HLA antibody and complement-binding activity

DSA was detected by using LABScreen Single Antigen (One Lambda Inc., A Thermo Fisher Scientific Brand, Canoga Park, CA, USA) as described in our previous report [6]. A mean fluorescence intensity (MFI) = 1,000 was used as a cut-off for positive results. Since 2009 we have been testing kidney recipients pretransplant and posttransplant for DSA using SAB assay. Therefore, for 42 patients who received transplants before 2009, we included the patients with a negative pretransplant T- and B-cell flow cytometric crossmatch and had negative DSA result in posttransplant monitoring. All 119 patients (73.9%) who received transplants since January 2009 were continuously followed DSA monitoring (1–3, 6, 12 months post-transplant and annually thereafter). DSA was assigned for HLA-A, HLA-B, HLA-C, HLA-DR, and HLA-DQ antigens. For all dnDSA (+) sera, both C1q and C3d assays were performed using C1q
Table 1. Clinical characteristics of 161 patients.

| Characteristics                                      | N = 161 |
|------------------------------------------------------|---------|
| Age at transplantation (year, mean (SD))             | 42.2 (11.9) |
| Gender; male, n (%)                                  | 124 (77.0) |
| Re-transplantation, n (%)                            | 7 (4.3) |
| Deceased donor, n (%)                                | 55 (34.2) |
| Donor gender; male, n (%)                            | 72 (44.7) |
| Donor age(year, mean (SD))                           | 44.0 (12.7) |
| HLA mismatch, n (mean (SD))                          | 3.2 (1.6) |
| ABO incompatible, n (%)                              | 4 (2.5) |
| Blood type, n (%)                                    |         |
| A                                                    | 46 (28.6) |
| B                                                    | 48 (29.8) |
| O                                                    | 40 (24.8) |
| AB                                                   | 27 (16.8) |
| Desensitization, n (%)                               | 9 (5.6) |
| Immune suppressant, n (%)                            |         |
| Cyclosporin,                                         | 37 (23.0) |
| Tacrolimus                                           | 124 (77.0) |
| Time since dialysis (month, median)(n = 138)         | 25.9 |
| Post-KT months to biopsy, (month, median)            | 8.0 |
| Pre-KT PRA (n = 122)                                 |         |
| HLA class I                                          |         |
| 10–50%                                               | 11 (6.8) |
| >50%                                                 | 2 (1.2) |
| HLA class II                                         |         |
| 10–50%                                               | 8 (5.0) |
| >50%                                                 | 7 (4.3) |
| DSA at the time of biopsy                            |         |
| HLA class I only                                     | 19 (11.8) |
| HLA class II only                                    | 29 (18.0) |
| HLA class I + II                                     | 6 (3.7) |
| Clq +                                                | 17 (10.6) |
| C3d +                                                | 24 (14.9) |
| Clq + C3d +                                          | 15 (9.3) |
| Biopsy-proven AMR, n (%)                             | 24 (14.9) |
| Graft failure, n (%)                                 | 44 (27.3) |
| Primary renal disease, n (%)                         |         |
| Chronic glomerulonephritis                           | 62 (38.5) |
| DM                                                   | 26 (16.1) |
| HTN                                                  | 25 (15.5) |
| ADPKD                                                | 3 (1.9) |
| Others                                               | 9 (5.6) |
| Unknown                                              | 36 (22.4) |

Abbreviations: KT, Kidney transplantation; PRA, Panel reactive antibody; DM, Diabetes mellitus; HTN, Hypertension; ADPKD, Autosomal dominant polycystic kidney disease; AMR, antibody mediated rejection; dnDSA, de-novo donor specific HLA antibody

https://doi.org/10.1371/journal.pone.0207434.t001
Screen™ (One Lambda, CA, USA) and Lifecodes C3d detection (Lifecodes C3d detection, Immucor Transplant Diagnostics, Inc., Stamford, CT, USA), respectively. All tests were performed according to the manufacturer’s protocol. Beads with MFI of greater than 1000 were defined as positive in C1q and C3d assays, after considering the MFI values in C1q or C3d positive cases and previous report [24]. Prozone effect was suspected based on antibody response patterns and inconsistency between PRA screening test and SAB assay. In eight samples, SAB assays were retested after pretreatment with dilution, ethylenediaminetetraacetic acid (EDTA), dithiothreitol (DTT), or heat inactivation.

**Diagnosis and treatment of allograft rejection**

These biopsies were performed using a 16-gauge biopsy gun under ultrasonic localization as described in our previous study [29]. Based on Banff working classification, histopathological diagnosis was made [30]. To detect C4d deposition, indirect immunofluorescence staining was performed with monoclonal anti-complement protein C4d antibodies (Biogenesis, Poole, UK; dilution 1:50). C4d positivity was defined as C4d score ≥ 2 (focal or diffuse). Treatment of allograft rejection was as follows. When T cell mediated rejection was diagnosed, 3 to 5 daily boluses of intravenous methyl prednisolone (250 mg/day) were used followed by 5 to 7 days of oral steroid taper. Anti-thymocyte globulin was used for steroid therapy resistance. In case of AMR, plasmapheresis with intravenous immunoglobulin (IVIg) was used while rituximab was added in patients who did not respond. Response to AMR treatment was defined as negative for AMR at follow-up biopsy, reduction of serum creatinine level to ≤ 110% of baseline level and decreased proteinuria.

In patients with chronic AMR, rituximab and IVIg for 4 days and IV methylprednisolone (250 mg per bolus) twice daily for 3 days followed by oral steroid taper for 5 to 7 days were applied.

**Statistical analysis**

Results are described as mean ± SD or median and range for continuous variables. For categorical data, results are described as number and percentages. Comparisons of proportions among multiple subgroups were performed with Chi-square trend tests while comparisons between groups were performed using Mann–Whitney test. The concordance between C1q and C3d assay was evaluated by Cohen’s kappa coefficient. Graft loss was defined by the return to the long term dialysis, graft removal or patient’s death caused by graft related problem. Post-biopsy graft survival functions, censoring for death were compared using Kaplan-Meier analysis with log rank test. Multivariate analysis for graft survival were conducted using the Cox proportional hazards regression model. We included all variables with a P value < 0.1 in the univariate analysis into multivariate analysis using a stepwise backward analysis, as previously proposed [31]. We further applied the competing risk regression as sensitivity analyses where death of patients from different causes was considered as a competing event (n = 161 patients, 44 graft failure and 12 deaths). Statistical analysis was performed using MedCalc version 15.5 (MedCalc, Mariakerke, Belgium), STATA version 15.1 (StataCorp LLC., College Station, TX) and R 2.4.0 statistical software. Results with P < 0.05 were considered statistically significant.

**Results**

**Detection of dnDSA and complement binding activity**

Of 161 recipients, dnDSA were detected in 54 (33.5%) patients at the time of biopsy. The majority of patients (53.7%, n = 29) had only HLA class II dnDSA while 35.2% (n = 19) had dnDSA against only HLA class I. However, 11.1% (n = 6) had both HLA class I and class II dnDSA. Overall, 25 patients had HLA class I dnDSA and 35 patients had class II dnDSA. In 54
patients with dnDSAs, 31.5% (n = 17) had C1q+ dnDSAs, 44.4% (n = 24) had C3d+ dnDSAs, and 51.9% (n = 28) had non-complement binding dnDSAs. Of 26 patients with C1q or C3d binding activities, majority (57.7%, 15/26) were both C1q and C3d positive (C1q+/C3d+), two (7.7%) patients had only C1q positive (C1q+/C3d-) dnDSAs, and nine (34.6%) patients had only C3d positive (C1q-/C3d+) dnDSAs. Regarding HLA specificity, patients with HLA class II dnDSAs had higher frequency of complement activity compared to patients with HLA class I dnDSA [60.0% (21/35) versus 24.0% (6/25), \( P = 0.006 \)]. In comparison of two complement-binding assays, the overall concordance in 54 paired tests was 79.6% (k = 0.58). For HLA class I and HLA class II dnDSAs, concordance rates were 88.0% (k = 0.59) and 74.3% (k = 0.51), respectively. Regarding dnDSA beads detected, 54 patients had 71 dnDSAs, including 18 dnDSAs positive in C1q assays [HLA-A (n = 1), HLA-B (n = 4), HLA-C (n = 1), HLA-DQ (n = 11), HLA-DR (n = 1)] and 28 dnDSAs positive in C3d assays [HLA-A (n = 1), HLA-B (n = 3), HLA-DQ (n = 15), HLA-DR (n = 9)]. HLA-DQ was the most frequent dnDSA (61% of C1q+ dnDSA, 53.6% of C3d+ dnDSA) in both C1q and C3d assays. C3d assay showed higher positive rate in dnDSA against HLA-DR than C1q assay (32.1% vs 5.6%, \( P = 0.035 \)).

**MFI values of dnDSA stratified by HLA class and complement-binding activity**

After correction for the prozone effect of suspected samples, MFI values of IgG-SAB assay between complement-binding and non-binding dnDSA were compared. Results according to HLA class specificity are shown in Fig 2. For HLA class II dnDSAs, both C1q and C3d binding dnDSAs had higher MFI values than C1q- or C3d- dnDSAs (\( P < 0.001 \) and \( P < 0.001 \), respectively). For HLA class II reactive dnDSAs, C1q+ dnDSAs had higher MFI values [median:
Clinical characteristics of dnDSA-positive patients

Clinical characteristics and clinical outcomes were compared according to results of C1q and C3d assays (Table 2). No significant differences were noted in recipient age, gender, type of transplantation, CKD etiologies (data not shown), donor gender, age, or between dnDSA + and dnDSA- groups. Taking small numbers in the comparing groups into consideration, recipient age, donor age and immune suppressive regimen were different between C3d+ and C3d- patients. Patients with C3d + dnDSA showed higher level of proteinuria (at the time of biopsy) compared with C3d –dnDSA group at the time of biopsy (P = 0.039). C1q+ dnDSAs were associated with biopsy-proven AMR and graft failure with statistical significance (P = 0.005 and P = 0.026, respectively). C3d+ dnDSAs showed similar tendency of association without reaching statistical significance (P = 0.236 and P = 0.056, respectively).

Biopsy-proven AMR

Of 161 patients who underwent allograft biopsy, twenty-four (14.9%) patients were diagnosed with biopsy-proven AMR. The incidence of AMR in patients with dnDSA was significantly higher than that in patients without dnDSA (37.0% versus 3.7%, P < 0.001). In 54 dnDSA positive patients, complement binding activity of dnDSA enhanced the incidence of AMR: 25.0%

Table 2. Comparison of clinical characteristics according to dnDSA, C1q and C3d positivity.

|                        | dnDSA+  | dnDSA-  | C1q +  | C1q -  | C3d +  | C3d -  |
|------------------------|---------|---------|--------|--------|--------|--------|
| Age at transplantation, year (mean, SD) | 42.6 (10.9) | 42.0 (12.2) | 39.9 (9.8) | 43.9 (11.2) | 38.9 ± 7.8 | 45.6 ± 12.1* |
| Gender; male, n (%)    | 41 (75.9) | 83 (77.6) | 15 (88.2) | 26 (70.3) | 18 (75.0) | 23 (76.7) |
| Re-transplantation, n (%) | 3 (5.6)  | 4 (3.7)  | 1 (5.9)  | 2 (5.4)  | 1 (4.2)  | 2 (6.7)  |
| Deceased donor, n (%)  | 17 (31.5) | 38 (35.5) | 4 (23.5) | 13 (35.1) | 6 (25.0) | 11 (36.7) |
| Donor gender; male, n (%) | 20 (37.0) | 52 (48.6) | 8 (47.1) | 12 (32.4) | 10 (41.7) | 10 (33.3) |
| Donor age, year (mean, SD) | 42.9 (13.3) | 44.7 (12.3) | 40.8 (13.9) | 43.9 (13.1) | 38.4 (12.4) | 46.5 (13.0)* |
| ABO incompatible, n (%) | 4 (7.4)  | 0 (0.0)†  | 1 (5.9)  | 3 (8.1)  | 1 (4.2)  | 3 (10.0) |
| Desensitization, n (%)  | 7 (13.0) | 2 (1.9)†  | 2 (11.8) | 5 (13.5) | 1 (4.2)  | 6 (20.0) |
| Immune suppressant, n (%) | Cyclosporin, | 11 (20.4) | 26 (23.6) | 5 (29.4) | 6 (16.2) | 8 (33.3) | 3 (10.0)* |
| Tacrolimus            | 43 (79.6) | 81 (75.7) | 12 (70.6) | 31 (83.8) | 16 (66.7) | 27 (90.0)* |
| Serum Cr at the time of biopsy, mg/dl (mean, SD) | 2.40 (1.35) | 2.48 (1.71) | 2.48 (1.35) | 2.37 (1.37) | 2.72 (1.71) | 2.14 (0.93) |
| Proteinuria at the time of biopsy, g/g (mean, SD) | 1.05 (1.16) | 1.84 (3.61) | 1.29 (1.26) | 0.94 (1.11) | 1.41 (1.44) | 0.76 (0.78)* |
| Biopsy-proven AMR, n (%) | 20 (37.0) | 4 (3.7)†  | 11 (64.7) | 9 (24.3)† | 11 (45.8) | 9 (30.0) |
| Active AMR, n (%)       | 6 (11.1) | 2 (1.8)†  | 4 (23.5) | 2 (5.4)  | 3 (12.5) | 3 (10.0) |
| Chronic active AMR, n (%) | 14 (25.9) | 2 (1.9)†  | 7 (41.2) | 7 (18.9) | 8 (33.3) | 6 (20.0) |
| Graft failure, n (%)    | 20 (37.0) | 24 (22.4)† | 10 (58.8) | 10 (27.0)† | 12 (50.0) | 8 (26.7) |

*, † Significantly different at:
*P < 0.05,
† P < 0.005

Abbreviations: AMR, antibody mediated rejection; dnDSA, de-novo donor specific HLA antibody; Cr, creatinine

https://doi.org/10.1371/journal.pone.0207434.t002
of patients with C1q-C3d- dnDSA, 36.4% of patients with C1q+/C3d- or C1q-/C3d+ dnDSA, and 60.0% of patients with C1q+/C3d+ dnDSAs (P < 0.001, Chi-square for trend) (Fig 3). The incidence of AMR was not significantly different between patients with C1q+ dnDSA and those with C3d+ dnDSA [64.7% (11/17) versus 45.8 (11/24), P = 0.238]. Six patients with C1q+ or C3d+ HLA class I dnDSA had higher incidence of AMR compared to 14 patients with C1q- C3d- HLA class I dnDSA [83.3% (5/6) versus 31.9% (6/19), P = 0.030]. In terms of HLA class II, AMR rates between patients with complement-binding class II dnDSA and those with non-complement-binding class II dnDSA were 42.9% (9/21) versus 14.3% (2/14) (P = 0.079).

As shown in Table 3, HLA class I ± II dnDSA, C1q+ HLA class I ± II dnDSA and C3d+ HLA class I ± II dnDSA had higher odds ratio than those for HLA-class II only. When we analyzed diagnostic performance of C1q or C3d assay in the study population, C1q-binding ability of dnDSA was a better predictor of AMR than dnDSA (odds ratio: 18.5 versus 15.2).

The sensitivity and specificity of C1q+ dnDSA for AMR were 45.8% and 95.6%, respectively. Positive and negative predictive values of C1q+ dnDSA for AMR were 64.7% and 91.0%, respectively. C3d+ dnDSA also showed good specificity (90.5%) and NPV (90.5%). When we analyzed the diagnostic performance of C1q and C3d assays according to HLA class,
complement-binding HLA class I ± II dnDSA showed higher odds ratio for the development of AMR (27.2 for C1q+ and 19.5 for C3d+ dnDSA) compared to HLA class II only dnDSA (11.1 for C1q+ and 5.3 for C3d+ dnDSA).

### C4d detection and histopathological findings

Of 54 dnDSA+ patients, 21 (38.9%) patients had C4d positivity on allograft biopsy. Complement binding activity of dnDSA enhanced C4d positivity: 21.4% of patients with C1q-C3d-dnDSAs, 45.5% of patients with C1q or C3d dnDSAs, and 66.7% of patients with C1q+/C3d+ dnDSAs ($P < 0.001$, Chi-square for trend) (Fig 4). Both C3d+ dnDSA and C1q+ dnDSA were associated with C4d deposition in allograft tissue ($P < 0.001$). There was no significant difference in C4d positivity between patients with C1q+ dnDSAs and those with C3d+ dnDSAs [64.7% (11/17) versus 58.3% (14/24), $P = 0.684$].

Histopathological findings at the time of dnDSA detection were compared according to C1q and C3d positivity (Table 4). In Banff scores, interstitial inflammation (i), total inflammation (ti), chronic glomerulopathy (cg) and C4d score were significantly higher in patients with C1q+ or C3d+ dnDSAs than those without C1q/C3d dnDSA. However, there was no significant difference between patients with C1q+ dnDSA and those with C3d+ dnDSA.

### Post-biopsy graft survival

Forty-four patients lost their graft due to various reasons, including rejection ($n = 32$), interstitial fibrosis and tubular atrophy ($n = 6$), and recurrence of primary renal disease ($n = 4$), etc. Table 5 displays risk factors using Cox proportional hazards regression and competing risk models. In a univariate analysis, significant predictors for post-biopsy graft survival were serum creatinine ($\geq 2.5$ mg/dl) and proteinuria ($\geq 2.0$ g/g for spot urine protein to creatinine ratio) at the time of biopsy, dnDSA, C1q+, C3d+ and microvascular inflammation (MVI) in biopsy. In multivariate analysis via the Cox proportional hazards model, serum creatinine ($\geq 2.5$ mg/dl) and proteinuria ($\geq 2.0$ g/g) at the time of biopsy were significantly higher in patients with C1q+ or C3d+ dnDSA than those without C1q/C3d dnDSA. However, there was no significant difference between patients with C1q+ dnDSA and those with C3d+ dnDSA.

### Table 3. Risk of AMR development in 161 kidney transplant patients.

|                | Odds ratio (95% CI) | P-value | Sensitivity | Specificity | PPV | NPV |
|----------------|---------------------|---------|-------------|-------------|-----|-----|
| dnDSA          | 15.2 (4.8–47.4)     | $<0.001$| 83.3        | 75.2        | 37.0| 96.3|
| C1q+           | 18.5 (5.9–58.1)     | $<0.001$| 45.8        | 95.6        | 64.7| 91.0|
| C3d+           | 8.1 (3.0–21.6)      | $<0.001$| 45.8        | 90.5        | 45.8| 90.5|
| HLA class I ± II dnDSA | 7.4 (2.8–19.7)     | $<0.001$| 45.8        | 89.8        | 44.0| 90.4|
| C1q+           | 27.2 (2.9–255.8)    | 0.004   | 16.7        | 99.3        | 80.0| 87.2|
| C3d+           | 19.5 (1.9–195.6)    | 0.012   | 12.5        | 99.3        | 75.0| 86.6|
| HLA class II only dnDSA | 3.5 (1.4–9.1)     | 0.010   | 37.5        | 85.4        | 31.0| 88.6|
| C1q+           | 11.1 (2.9–43.1)     | $<0.001$| 25.0        | 97.1        | 60.0| 88.1|
| C3d+           | 5.3 (1.8–15.6)      | 0.003   | 29.2        | 92.7        | 41.2| 88.2|

Abbreviations: AMR, antibody mediated rejection; dnDSA: de novo donor-specific HLA antibodies; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value.
poorest post biopsy survival in Fig 5D. Although no significance was found ($P = 0.642$), the graft failure occurred earlier in patients with complement binding HLA class I ± II dnDSA compared to patients with complement binding HLA-class II only dnDSA. We also analyzed the impact of C1q and C3d binding dnDSA in post biopsy graft survival stratified for AMR status, but there was no statistical significance (S1 Fig). When we analyzed 50% reduction in estimated glomerular filtration rate (eGFR) as a surrogate marker of long-term allograft survival, complement-binding dnDSA showed also association with eGFR decline (Fig 6).

**Discussion**

In present study, we retrospectively detected complement-binding activity of DSA detected at the time of biopsy in 161 pretransplant DSA-negative patients. Lately, it has been shown that
Table 4. Banff histology by C1q and C3d status in 161 recipients.

| Banff score (mean, SD) | C1q+ dnDSA (N = 17) | C3d+ dnDSA (N = 24) | C1q-C3d- dnDSA (N = 28) | dnDSA- (N = 107) |
|------------------------|---------------------|---------------------|-------------------------|------------------|
| Glomerulitis (g)       | 1.76 (1.25) †       | 1.54 (1.28) †       | 1.11 (1.13) †           | 0.36 (0.79)       |
| Tubulitis (t)          | 1.12 (1.17)         | 1.13 (1.12)         | 0.75 (1.08)             | 0.62 (0.95)       |
| Interstitial inflammation (i) | 2.12 (0.78) * †     | 2.13 (0.85) * †     | 1.25 (0.93)             | 1.22 (0.94)       |
| Intimal arteritis (v)  | 0.18 (0.53)         | 0.17 (0.48)         | 0.11 (0.42)             | 0.10 (0.39)       |
| Arteriolar hyaline thickening (ah) | 0.53 (0.87)       | 0.46 (0.78)         | 0.18 (0.67)             | 0.42 (0.91)       |
| Peritubular capillaritis (ptc) | 2.12 (1.27) †      | 1.75 (1.29) †       | 1.64 (1.37) †           | 0.25 (0.67)       |
| Total inflammation (ti) | 2.24 (0.75) †       | 2.29 (0.75) †       | 1.57 (0.92)             | 1.23 (0.95)       |
| Chronic glomerulopathy (cg) | 1.24 (1.52) †       | 1.13 (1.48) †       | 0.36 (0.83)             | 0.07 (0.45)       |
| Chronic changes in tubules (ct) | 1.12 (0.93)         | 1.21 (0.88)         | 0.96 (0.74)             | 0.80 (1.00)       |
| Chronic changes in the interstitium (ci) | 1.12 (0.93)         | 1.21 (0.88)         | 0.96 (0.74)             | 0.77 (1.01)       |
| Chronic changes in vessels (cv) | 0.12 (0.49)         | 0.08 (0.41)         | 0.00 (0.00)             | 0.01 (0.09)       |
| Mesangial matrix increase (mm) | 0.88 (0.93)         | 0.79 (0.84)         | 0.50 (0.75)             | 0.43 (0.72)       |
| C4d score              | 1.94 (1.48) †       | 1.79 (1.47) †       | 0.77 (1.27) †           | 0.10 (0.49)       |
| Histologic diagnosis (N, %) |                     |                     |                         |                  |
| MVI                    | 13 (76.5) †         | 18 (75.0) †         | 19 (67.9) †             | 21 (19.6)         |
| IFTA                   | 2 (11.8)            | 6 (25.0)            | 9 (32.1)                | 23 (21.5)         |
| TCMR                   | 6 (35.3)            | 8 (33.3)            | 4 (14.3)                | 27 (25.2)         |

Abbreviations: MVI, microvascular inflammation (g+ptc ≥ 2); TCMR, T cell-mediated rejection; IFTA, interstitial fibrosis and tubular atrophy.
* P < 0.05 compared with C1q-C3d- dnDSA group.
† P < 0.05 compared with dnDSA- group.

https://doi.org/10.1371/journal.pone.0207434.t004

Table 5. Cox regression analysis for graft failure associated risk factors and competing risk analysis.

| Cox regression | HR (95% CI) | P-value | SHR† (95% CI) | P-value |
|----------------|-------------|---------|--------------|---------|
| Univariate analysis |             |         |              |         |
| Recipient age, year | 1.00 (0.98–1.03) | 0.978    | 1.00 (0.97–1.02) | 0.807   |
| Sex (male)          | 1.67 (0.74–3.74) | 0.214    | 1.62 (0.72–3.64) | 0.243   |
| Retransplantation   | 1.04 (0.25–4.31) | 0.955    | 1.09 (0.29–4.19) | 0.895   |
| No. mismatch HLA A/B/DR | 1.05 (0.88–1.26) | 0.566    | 1.05 (0.87–1.28) | 0.584   |
| Cr (≥ 2.5 mg/dL)   | 4.45 (2.46–8.03) | <0.001   | 4.58 (2.54–8.24) | <0.001  |
| Proteinuria (≥ 2.0 g/g) | 5.61 (3.11–10.14) | <0.001   | 5.11 (2.83–9.21) | <0.001  |
| Deceased donor     | 1.03 (0.55–1.91) | 0.937    | 0.98 (0.53–1.81) | 0.945   |
| dnDSA              | 2.21 (1.20–4.05) | 0.011    | 2.19 (1.19–4.03) | 0.012   |
| C1q+ dnDSA         | 2.90 (1.43–5.89) | 0.003    | 3.05 (1.58–5.87) | 0.001   |
| C3d+ dnDSA         | 2.82 (1.46–5.43) | 0.002    | 2.97 (1.58–5.57) | 0.001   |
| C1q+ C3d+ dnDSA    | 2.78 (1.33–5.81) | 0.006    | 2.93 (1.51–5.67) | 0.001   |
| C4d+               | 1.64 (0.81–3.33) | 0.172    | 1.73 (0.90–3.34) | 0.101   |
| MVI                | 1.86 (1.03–3.37) | 0.040    | 1.91 (1.05–3.47) | 0.033   |
| Multivariate analysis |             |         |              |         |
| Cr (≥ 2.5 mg/dL)   | 3.45 (1.85–6.43) | <0.001   | 3.64 (1.95–6.78) | <0.001  |
| Proteinuria (≥ 2.0 g/g) | 3.82 (2.01–7.29) | <0.001   | 3.49 (1.84–6.62) | <0.001  |

*Hazard ratios are from Cox proportional regression model (n = 161 patients and 44 graft failure)
†Subdistribution hazard ratios are from competing risk models when death was treated as competing risk (n = 161 patients, 12 deaths and 44 graft failure)
**at the time of renal biopsy
Abbreviations: MVI, microvascular inflammation (g+ptc ≥ 2); dnDSA: de novo donor-specific HLA antibodies; Cr, serum creatinine

https://doi.org/10.1371/journal.pone.0207434.t005
DSA monitoring combined with C1q or C3d binding activity provides more predictive value for allograft outcome compared to the non-complement binding DSA [15, 18–22, 32–36]. This study evaluated both C1q and C3d activity of DSA and our results showed that complement-binding assay further stratified dnDSA+ patients at risk of poor graft outcomes, with C1q+/C3d+ HLA class I dnDSA having the highest incidence for AMR.

We found that 33.5% (n = 54) of recipients had dnDSA and 48.1% of dnDSAs (n = 26) had complement-binding activity. This result is similar to a previous study showing that 55.4–67.5% of dnDSAs have complement binding activity [24, 34]. When we stratified patients by HLA class specificity, only 26.3% of HLA class I-reactive dnDSA had complement binding activity while the majority (58.6%) of HLA class II dnDSA had C1q or C3d positivity. This result supports a previous study showing that 70.3% of HLA class II-reactive DSA binds C3d [34]. Higher IgG MFI of HLA class II dnDSA than HLA class I (shown in Fig 2) might lead to greater complement binding dnDSA as discussed above. In this study, we detected dnDSA by using LABscreen assay. Therefore, we cannot rule out that dnDSA might be detected using Immucore assay only. However, a previous study has shown agreement exceeding 90% between laboratories and kits [37]. Therefore, this difference would not have had a significant impact on the results. In

Fig 5. Post-biopsy graft survival according to complement binding activity. (A) C1q binding dnDSA correlated with post-biopsy graft survival (Log rank, \( P = 0.005 \)). (B) C3d binding dnDSA correlated with post-biopsy graft survival (Log rank, \( P = 0.012 \)). (C) The presence of complement binding dnDSA correlated with post-biopsy graft survival (Log rank, \( P = 0.002 \)). In this comparison, fifteen patients with C1q+ and C3d+ dnDSA are overlapped as they also belonged to the group of dnDSA+ C1q+ or C3d+. (D) Patients with complement binding HLA class I ± II dnDSA showed early graft failure.

https://doi.org/10.1371/journal.pone.0207434.g005
comparison of two complement-binding assays, C1q and C3d assays showed moderate strength of agreement (kappa coefficient of 0.58). The disagreement of C1q and C3d assay was already observed in a previous report [24]. The specific difference or functional characteristics of antibodies in the assays needs to be addressed in the future [24].

Correlation between MFI value and C1q/C3d positivity has been previously reported [34, 38, 39]. Similarly, we found that complement binding activity was closely related to strength of HLA antibodies. The relationship seems appropriate as higher MFIs correlate with higher antibody titers, making greater antibody binding and enhancing multivalent C1q binding avidity [40].
However, using MFI as a surrogate for determining complement activating capacity of HLA antibodies remains debatable as not all studies have shown this relationship [16, 41, 42]. In our results, complement binding dnDSAs had higher MFI values than C1q- or C3d- dnDSAs, especially HLA class II dnDSA. However, C3d+ dnDSA against HLA class II showed a large overlap between MFI values while a clear threshold could not be determined, similar to a previous report showing poor correlation between IgG MFI and C3d results [24].

In present study, both C1q+ and C3d+ dnDSAs were associated with more C4d staining. Complement binding activity of dnDSA enhanced the incidence of AMR: 25.0% in C1q-C3d-, 36.4% in C1q+/C3d- or C1q-/C3d+, and 60.0% in C1q+/C3d+ patients (P < 0.001). However, in comparison between C1q and C3d assays, C3d assay could not significantly differentiate AMR in dnDSA+ patients. Although the incidence of AMR was not significantly different between C1q+ and C3d+ patients [64.7% (11/17) versus 45.8 (11/24), P = 0.238], these findings were not concordant with those of previous studies which showed lower proportion of C3d positivity and better prognostic predictability with C3d assay [22, 24]. This might be due to different study population including higher proportion of dnDSAs against HLA class II antigen or different post-KT duration until allograft biopsy. In our study, nine patients with C1q-C3d+ dnDSA had only HLA class II dnDSA and two of them were diagnosed as AMR. The discrepancy in results could be due to interference in C1q assay, such as the presence of denatured HLA antigen, complement interference or the detection of potentially non-significant antibody [24, 43]. Further studies are needed to confirm the specific difference or functional characteristics.

However, C1q+ dnDSAs was better diagnostic predictors for AMR than total dnDSA in present study. Especially, C1q+ HLA class I ± II dnDSA was the best predictor for AMR (odds ratio: 27.2). However, clinical outcomes were not significantly different between C1q+ and C3d+ dnDSA-positive patients.

Monitoring of post-transplant serum DSA is noninvasive and serial test is easy compared to C4d staining. C4d is a specific marker for AMR. However, it lacks sensitivity, particularly for late AMR [44]. DSA detection has identified patients with high risk for graft failure despite C4d negativity in biopsy [45, 46]. In line with these findings, although we cannot confirm the independent predictive value of C1q and C3d, our results support the notion that post-transplant DSA monitoring with complement binding assay would be a better prognostic marker after kidney transplantation than C4d stain.

This study has some limitations. Although our results demonstrated significant association between complement binding dnDSA and AMR, the results were derived from a selected population undergoing indication graft biopsy with different follow-up durations and might not be extended to the general population of kidney recipients. In addition, we could not specify dnDSAs against DQ alpha and beta protein though AMR due to DQ alpha protein-specific HLA antibody was reported [47].

In conclusion, our results suggest that detection of complement binding activity using both C1q and C3d assays can be a further prognostic marker for predicting AMR and allograft outcome in dnDSA+ kidney transplant patients. Thus, C1q or C3d binding assay might be used as a complementary test to conventional IgG assay in assessing the risk of AMR.

Supporting information

S1 Fig. Post-biopsy graft survival stratified for AMR status. Post biopsy graft survival according to the C1q positivity in patients with AMR (A) and without AMR (B). Post biopsy graft survival according to the C3d positivity in patients with AMR (C) and without AMR (D). Although there was no statistical significance, patients with C1q+ dnDSA and C3d+dnDSA showed inferior post biopsy graft survival, especially in AMR negative group (Log rank,
\( P = 0.116 \) for C1q and \( P = 0.234 \) for C3d).

**Acknowledgments**

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (NRF-2017R1A2B4011181), Republic of Korea.

**Author Contributions**

**Conceptualization:** Eun-Jee Oh.

**Data curation:** Tae Hyun Ban, Byung Ha Chung, Yeong Jin Choi.

**Formal analysis:** Hyeyoung Lee, Eunhee Han.

**Funding acquisition:** Eun-Jee Oh.

**Investigation:** Eunhee Han, Tae Hyun Ban, Byung Ha Chung.

**Methodology:** Eunhee Han, Ae-Ran Choi, Yeong Jin Choi.

**Project administration:** Eun-Jee Oh.

**Resources:** Eun-Jee Oh.

**Supervision:** Chul Woo Yang, Eun-Jee Oh.

**Validation:** Hyeyoung Lee, Eun-Jee Oh.

**Visualization:** Hyeyoung Lee, Eun-Jee Oh.

**Writing – original draft:** Hyeyoung Lee, Eun-Jee Oh.

**Writing – review & editing:** Hyeyoung Lee, Eun-Jee Oh.

**References**

1. Sellares J, de Freitas DG, Mengel M, Reeve J, Einecke G, Sis B, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2012; 12(2):388–99. Epub 2011/11/16. https://doi.org/10.1111/j.1600-6143.2011.03840.x. PMID: 22081892.

2. Lan JH, Tinckam K. Clinical Utility of Complement Dependent Assays in Kidney Transplantation. Transplantation. 2018; 102(1S Suppl 1):S14–s22. Epub 2017/12/22. https://doi.org/10.1097/tp.0000000000001819 PMID: 29266058.

3. Tait BD. Detection of HLA Antibodies in Organ Transplant Recipients—Triumphs and Challenges of the Solid Phase Bead Assay. Frontiers in immunology. 2016; 7:570. Epub 2016/12/27. https://doi.org/10.3389/fimmu.2016.00570 PMID: 28018342; PubMed Central PMCID: PMC5146910.

4. Oh EJ, Park H, Park KU, Kang ES, Kim HS, Song EY. Interlaboratory Comparison of the Results of Locus-specific Single Antigen Kits for Human Leukocyte Antigen Antibody Detection. Annals of laboratory medicine. 2015; 35(3):321–8. Epub 2015/05/02. https://doi.org/10.3343/alm.2015.35.3.321 PMID: 25932440; PubMed Central PMCID: PMCPMC4390700.

5. Kauke T, Oberhauser C, Lin V, Coenen M, Fischereder M, Dick A, et al. De novo donor-specific anti-HLA antibodies after kidney transplantation are associated with impaired graft outcome independently of their C1q-binding ability. Transplant international: official journal of the European Society for Organ Transplantation. 2017; 30(4):360–70. Epub 2016/11/20. https://doi.org/10.1111/tri.12887 PMID: 27862352.

6. Lee H, Min JW, Kim J, Moon IS, Park KH, Yang CW, et al. Clinical Significance of HLA-DQ Antibodies in the Development of Chronic Antibody-Mediated Rejection and Allograft Failure in Kidney Transplant Recipients. Medicine. 2016; 95(11):e3094. Epub 2016/03/18. https://doi.org/10.1097/md.0000000000003094 PMID: 26986147; PubMed Central PMCID: PMCPMC4839928.
7. de Kort H, Williccombe M, Brookes P, Dominy KM, Santos-Nunez E, Galliford JW, et al. Microcirculation inflammation associates with outcome in renal transplant patients with de novo donor-specific antibodies. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2013; 13(2):485–92. Epub 2012/11/22. https://doi.org/10.1111/1660-6143.2012.04325.x PMID: 23167441.

8. Caro-Oleas JL, Gonzalez-Escrribano MF, Genti-Govantes MA, Acevedo MJ, Gonzalez-Roncero FM, Blanco GB, et al. Clinical relevance of anti-HLA donor-specific antibodies detected by Luminex assay in the development of rejection after renal transplantation. Transplantation. 2012; 94(4):338–44. Epub 2012/07/21. https://doi.org/10.1097/TP.0b013e3182b5ace2c PMID: 22814339.

9. Ntokou IS, Iniotaki AG, Kontou EN, Darema MN, Apostoliak MD, Kostakis AG, et al. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules. Transplant international: official journal of the European Society for Organ Transplantation. 2011; 24(11):1084–93. Epub 2011/08/19. https://doi.org/10.1111/j.1399-3046.2011.01312.x PMID: 21848902.

10. Cooper JE, Gralla J, Cagle L, Goldberg R, Chan L, Wiseman AC. Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes. Transplantation. 2011; 91(10):1103–9. Epub 2011/03/16. https://doi.org/10.1097/TP.0b013e3182139da1 PMID: 21403588.

11. Wiebe C, Gibson Iw, Blydt-Hansen TD, Karpinski M, Ho J, Storsley LJ, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2012; 12(5):1157–67. Epub 2012/03/21. https://doi.org/10.1111/j.1600-6143.2012.04013.x PMID: 22429309.

12. Everly MJ, Everly JJ, Arend LJ, Brailey P, Susskind B, Govil A, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2009; 9(5):1063–71. Epub 2009/04/07. https://doi.org/10.1111/j.1600-6143.2009.02577.x PMID: 19344434.

13. Tyan DB. New approaches for detecting complement-fixing antibodies. Current opinion in organ transplantation. 2012; 17(4):409–15. Epub 2012/06/20. https://doi.org/10.1097/MOT.0b013e328355fb9b PMID: 22710386.

14. Min JW, Lee H, Choi BS, Park CW, Yang CW, Kim YS, et al. Clinical Impact of Pre-transplant Antibodies Against Angiotensin II Type I Receptor and Major Histocompatibility Complex Class I-Related Chain A in Kidney Transplant Patients. Annals of laboratory medicine. 2018; 38(5):450–7. https://doi.org/10.3343/alm.2018.38.5.450 PMID: 29797816

15. Sicard A, Ducreux S, Rabeyrin M, Couzi L, McGregor B, Badet L, et al. Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. Journal of the American Society of Nephrology: JASN. 2015; 26(2):457–67. Epub 2014/08/16. https://doi.org/10.1681/ASN.2013101144 PMID: 25123923; PubMed Central PMCID: PMC4310553.

16. Chen G, Sequeira F, Tyan DB. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Human immunology, 2011; 72(10):949–58. Epub 2011/07/29. https://doi.org/10.1016/j.humimm.2011.07.001 PMID: 21791230.

17. Calp-Inal S, Ajsaimy M, Melamed ML, Savchik C, Masaiakos P, Colovai A, et al. The prevalence and clinical significance of C1q-binding donor-specific anti-HLA antibodies early and late after kidney transplantation. Kidney international. 2016; 89(1):209–16. Epub 2015/11/05. https://doi.org/10.1038/ki.2015.275 PMID: 26535999.

18. Sutherland SM, Chen G, Sequeira FA, Lou CD, Alexander SR, Tyan DB. Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatric transplantation. 2012; 16(1):12–7. Epub 2011/11/19. https://doi.org/10.1111/j.1399-3046.2011.01599.x PMID: 22093755.

19. Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong van Huyen JP, Mooney N, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. The New England journal of medicine. 2013; 369(13):1215–26. Epub 2013/09/27. https://doi.org/10.1056/NEJMoa1302506 PMID: 24066742.

20. Yabu JM, Higgins JP, Chen G, Sequeira F, Busque S, Tyan DB. C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation. 2011; 91(3):342–7. Epub 2010/12/01. https://doi.org/10.1097/TP.0b013e318203fd26 PMID: 21116220.

21. Ramon DS, Huang Y, Zhao L, Rendulic T, Park JM, Sung RS, et al. Use of complement binding assays to assess the efficacy of antibody mediated rejection therapy and prediction of graft survival in kidney
transplantation. Human immunology. 2017; 78(2):57–63. Epub 2016/11/30. https://doi.org/10.1016/j.humimm.2016.11.009 PMID: 27894836.

22. Comoli P, Cioni M, Tagliamaccio A, Quartiuccio G, Innocente A, Fontana I, et al. Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Sensitized Pediatric Kidney Recipients. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2016; 16(7):2106–16. Epub 2016/01/05. https://doi.org/10.1111/ajt.13700 PMID: 26725780.

23. Eskandary F, Bond G, Kozakowski N, Regele H, Marinova L, Wahlmann M, et al. Diagnostic Contribution of Donor-Specific Antibody Characteristics to Uncover Late Silent Antibody-Mediated Rejection-Results of a Cross-Sectional Screening Study. Transplantation. 2017; 101(3):631–41. Epub 2016/04/28. https://doi.org/10.1097/TP.0000000000001195 PMID: 27120452.

24. Kim JJ, Shaw O, Martin C, Michaelides G, Balasubramanian R, Sebire NJ, et al. Clinical risk stratification of paediatric renal transplant recipients using C1q and C3d fixing of de novo donor-specific antibodies. Pediatric nephrology (Berlin, Germany). 2018; 33(1):167–74. Epub 2017/09/18. https://doi.org/10.1007/s00467-017-3772-7 PMID: 28918487; PubMed Central PMCID: PMCPMC5700253.

25. Chung BH, Kim KW, Kim BM, Piao SG, Lim SW, Choi BS, et al. Dysregulation of Th17 cells during the early post-transplant period in patients under calcineurin inhibitor based immunosuppression. PLoS one. 2012; 7(7):e42011. Epub 2012/08/01. https://doi.org/10.1371/journal.pone.0042011 PMID: 22848688; PubMed Central PMCID: PMCPMC3405048.

26. Kim Y, Park KH, Chung BH, Choi BS, Yang CW, Kim JI, et al. Pretransplant IFN-gamma ELISPOT assay as a potential screening test to select immunosuppression protocols for patients receiving basiliximab induction therapy. Translational research: the journal of laboratory and clinical medicine. 2012; 160(3):230–6. Epub 2012/06/12. https://doi.org/10.1016/j.trsl.2012.02.009 PMID: 22883414.

27. Chung BH, Choi BS, Oh EJ, Park CW, Kim JI, Moon IS, et al. Clinical impact of the baseline donor-specific anti-human leukocyte antigen antibody measured by Luminox single antigen assay in living donor kidney transplant recipients after desensitization therapy. Transplant international: official journal of the European Society for Organ Transplantation. 2014; 27(1):49–59. Epub 2013/10/15. https://doi.org/10.1111/tri.12199 PMID: 24118413.

28. Park HS, Hong Y, Sun IO, Chung BH, Kim HW, Choi BS, et al. Effects of pretransplant plasmapheresis and rituximab on recurrence of focal segmental glomerulosclerosis in adult renal transplant recipients. The Korean journal of internal medicine. 2014; 29(4):482–8. Epub 2014/07/22. https://doi.org/10.3904/kjm.2014.29.4.482 PMID: 25045296; PubMed Central PMCID: PMCPMC4101595.

29. Chung BH, Lee JY, Kang SH, Sun IO, Choi SR, Park HS, et al. Comparison of clinical outcome between high and low baseline anti-ABO antibody titers in ABO-incompatible kidney transplantation. Renal failure. 2011; 33(2):150–8. Epub 2011/02/22. https://doi.org/10.3109/0886022X.2011.552149 PMID: 21332336.

30. Haas M, Loupy A, Lefaucheur C, Roufosse C, Glotz D, Seron D, et al. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2018; 18(2):293–307. Epub 2017/12/16. https://doi.org/10.1111/ajt.14625 PMID: 29243394; PubMed Central PMCID: PMCPMC5817248.

31. Heinze G, Dunkler D. Five myths about variable selection. Transplant international: official journal of the European Society for Organ Transplantation. 2017; 30(1):6–10. Epub 2016/11/30. https://doi.org/10.1111/tri.12895 PMID: 27896674.

32. Freitas MC, Rebellato LM, Ozawa M, Nguyen A, Sasaki N, Everly M, et al. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation. 2013; 95(9):1113–9. Epub 2013/03/22. https://doi.org/10.1097/TP.0b013e3182888d6d PMID: 23514959.

33. Guidicelli G, Guerville F, Lepreux S, Wiebe C, Thaunat O, Dubois V, et al. Non-Complement-Binding De Novo Donor-Specific Anti-HLA Antibodies and Kidney Allograft Survival. Journal of the American Society of Nephrology: JASN. 2016; 27(2):615–25. Epub 2015/06/07. https://doi.org/10.1681/ASN.2014040326 PMID: 26047793; PubMed Central PMCID: PMCPMC4731103.

34. Pelletier RP, Balazs I, Adams P, Rajab A, DiPaola NR, Henry ML. Clinical utility of C3d binding donor-specific anti-human leukocyte antigen antibody detection by single antigen beads after kidney transplantation-a retrospective study. Transplant international: official journal of the European Society for Organ Transplantation. 2018; 31(4):424–35. Epub 2017/12/22. https://doi.org/10.1111/tri.13106 PMID: 29265514.

35. Viglietti D, Bousquet Y, Khea VD, Aubert O, Suberbielle-Boissel C, Glotz D, et al. Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with...
antibody-mediated rejection. Kidney international. 2018. Epub 2018/05/29. https://doi.org/10.1016/j.kint.2018.03.015 PMID: 29801667.

36. Lan JH, Gjertson D, Zheng Y, Clark S, Reed EF, Cecka MJ. Clinical utility of complement-dependent C3d assay in kidney recipients presenting with late allograft dysfunction. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2018. Epub 2018/04/17. https://doi.org/10.1111/ajt.14871 PMID: 29659162.

37. Reed EF, Rao P, Zhang Z, Gebel H, Bray RA, Guleria I, et al. Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2013; 13(7):1859–70. Epub 2013/06/15. https://doi.org/10.1111/ajt.12287 PMID: 23763489; PubMed Central PMCID: PMC3967448.

38. Claisse G, Abi L, Cognasse F, Alamartine E, Mariat C, Maillard N. Relationship between Mean Fluorescence Intensity and C1q/C3d-fixing capacities of anti-HLA antibodies. Human immunology. 2017; 78(4):336–41. Epub 2017/02/13. https://doi.org/10.1016/j.humimm.2017.02.003 PMID: 28189573.

39. Yell M, Muth BL, Kaufman DB, Djamali A, Ellis TM. C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody-mediated Rejection. Transplantation. 2015; 99(6):1151–5. Epub 2015/04/04. https://doi.org/10.1097/TP.0000000000000699 PMID: 25839705.

40. Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA, et al. Complement is activated by IgG hexamers assembled at the cell surface. Science (New York, NY). 2014; 343(6176):1260–3. Epub 2014/03/15. https://doi.org/10.1126/science.1248943 PMID: 24626930; PubMed Central PMCID: PMC4250092.

41. Lachmann N, Todorova K, Schulze H, Schonemann C. Systematic comparison of four cell- and Luminex-based methods for assessment of complement-activating HLA antibodies. Transplantation. 2013; 95(5):694–700. Epub 2013/01/29. https://doi.org/10.1097/TP.0b013e31827b3dc3 PMID: 23354296.

42. Llorente S, Boix F, Eqvia J, Lopez M, Bosch A, Martinez H, et al. C1q-fixing human leukocyte antigen assay in immunized renal patients: correlation between Luminex SAB-C1q and SAB-IgG. Transplantation proceedings. 2012; 44(9):2535–7. Epub 2012/11/14. https://doi.org/10.1016/j.transproceed.2012.09.084 PMID: 23146446.

43. Taylor CJ, Kosmoliaptis V, Martin J, Knighton G, Mallon D, Bradley JA, et al. Technical Limitations of the C1q Single-Antigen Bead Assay to Detect Complement Binding HLA-Specific Antibodies. Transplantation. 2017; 101(6):1206–14. Epub 2016/06/17. https://doi.org/10.1097/TP.0000000000001270 PMID: 27306532.

44. Djamali A, Kaufman DB, Ellis TM, Zhong W, Matas A, Samaniego M. Diagnosis and management of antibody-mediated rejection: current status and novel approaches. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2014; 14(2):255–71. Epub 2014/01/10. https://doi.org/10.1111/ajt.12589 PMID: 24401076; PubMed Central PMCID: PMC4285166.

45. Sellares J, Reeve J, Loupy A, Mengel M, Sis B, Skene A, et al. Molecular diagnosis of antibody-mediated rejection in human kidney transplants. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2013; 13(4):971–83. Epub 2013/02/19. https://doi.org/10.1111/ajt.12150 PMID: 23414212.

46. Loupy A, Hill GS, Suberbielle C, Charron D, Anglicheau D, Zuber J, et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2011; 11(1):56–65. Epub 2011/01/05. https://doi.org/10.1111/j.1600-6143.2010.03364.x PMID: 21193348.

47. SH S, BG P, BS K, YS K, HS K. Two Cases of Antibody-Mediated Rejection Following Kidney Transplantation due to HLA-DQB1 Allele-Specific and DQ Alpha Protein-Specific HLA Antibodies. Annals of laboratory medicine. 2017; 37(3):290–2. https://doi.org/10.3343/alm.2017.37.3.290 PMID: 28224780.